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HCV Core plays a role in the development of hepatocellular carcinoma. Aberrant expression of
NANOG has been observed in many types of human malignancies. However, relationship between
Core and NANOG has not been clariﬁed. In this study, we found that Core is capable of up-regulating
NANOG expression. Core-induced NANOG expression was accompanied by enforced expression of
phosphorylated stat3 protein and was attenuated by inhibition of stat3 phosphorylation. ChIP
showed that phosphorylated stat3 directly binds to the NANOG promoter. Core-induced NANOG
expression resulted in enhanced cell growth and cell cycle progression. Knockdown of NANOG
blocked the cell cycle at the G0/G1 phases and inhibited the cyclin D1 expression. Our ﬁndings pro-
vide a new insight into the mechanism of hepatocarcinogenesis by HCV infection.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV), a major etiological agent of non-A and
non-B hepatitis, is a major cause of chronic hepatitis, liver cirrhosis
and hepatocellular carcinoma (HCC) worldwide [1]. The precise
mechanism by which HCV infection results in the development
of HCC remains largely unknown. HCV is a positive-strand RNA
virus classiﬁed as a hepacivirus of the family Flaviviridae [2].
Among the four putative structural (core, E1, E2, p7) and six
non-structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins, the
21 kDa HCV Core has attracted special attention after its character-
ization and various studies have suggested its potential role in HCV
pathogenesis [3]. HCV Core has been reported to interact with sev-
eral proteins including TNFR, PKR, Stat3 and p53 in order to mod-
ulate the downstream genes of these proteins and consequently to
modulate numbers of cellular regulatory functions [4]. In addition,
numerous studies have suggested a direct involvement of HCV
core protein in the modulation of cell proliferation, apoptosis,transformation and immortalization, including the promotion of
immortalization of human hepatocytes by activation of Stat3
and its downstream molecules [5]. Many reports demonstrated
that HCV Core-induced molecular alterations in infected cells
contribute largely to HCC development and progression. Further-
more, direct induction of HCC by HCV Core in transgenic mice
has been reported [6]. Although a strong relationship between
HCV-induced HCC is now generally accepted, the molecular
mechanism of HCV-induced, especially HCV Core-induced
hepatocarcinogenesis is still not clearly understood.
The NANOG gene, a member of the homeobox family of DNA
binding transcription factors, was recently identiﬁed in a screen
for pluripotency promoting genes. NANOG is now known as a mas-
ter transcription factor essential for maintaining cell stemness, and
is speciﬁcally expressed in embryonic pluripotent stem cells,
NANOG acts together with Oct4 and SOX2 to maintain the prolifer-
ation and self-renewal of embryonic stem cells (ESC) [7]. The prop-
erties of ESCs are very similar with cancer cells, such as fast
proliferation and poor differentiation state. Indeed, NANOG has
demonstrated a role in the development of solid tumors recently,
and accumulating evidence showed that NANOG is expressed in
several types of human cancers, such as embryonic carcinoma
[8], breast cancer [9], glioma [10], retinoblastoma [11], colon can-
cer [12] and ovarian cancer cell line SKOV3 [13], suggesting that
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demonstrate that NANOG expression is regulated by viral oncopro-
teins [14]. Using animal model and in vitro cell systems Machida
et al. showed evidences that HCV NS5A cooperative with alcohol
induced expression of NANOGmessenger RNA (mRNA) and protein
in HCC cells and tumor-bearing tissue [14], indicating that aberrant
NANOG expression and function were involved in hepatic onco-
genesis of HCV-related HCC.
The signal transducer and activator of transcription (STAT) fam-
ily proteins have been identiﬁed almost two decades as transcrip-
tion factors that are activated in response to various extracellular
polypeptide ligands including cytokines and growth factors, and
been found participated in numerous cytokine signaling widely
[15]. In addition to their important role in normal cell signaling
pathways, numerous studies have suggested that abnormal acti-
vating of STAT signalings, especially STAT3, directly contributes
to malignant transformation of cells [16]. However, although Yos-
hida et al. have discovered that STAT3 activation by the HCV core
protein is an important step for HCV-induced hepatocarcinogene-
sis [5], the detailed role of STAT3 in HCV core related HCC is still
little studied and remains unknown till now.
In this study, we explored the role of HCV Core in the regulation
of NANOG expression as well as the potential molecular mecha-
nisms. Using the HepG2 cell line we demonstrated that NANOG
expression was up-regulated by Core stimulation. Core-induced
NANOG expression was abolished following the RNA interfer-
ence-mediated silencing of Core. In addition, the Core-induced NA-
NOG expression was accompanied by enforced expression of
phosphorylated stat3 protein and was attenuated by inhibition of
stat3 phosphorylation via AG490 treatment, phosphorylated stat3
protein directly binds to the promoter of NANOG and regulates NA-
NOG expression. Furthermore, Core-induced NANOG expression
promoted cell growth and cell cycle progression. Knockdown of
NANOG blocked the cell cycle at the G0/G1 phases and inhibited
the cyclin D1 expression in Core-expressing cells. Altogether, these
results proposed a new mechanism by which HCV Core regulates
expression of NANOG. Our ﬁndings provide a new insight into
the mechanism of hepatocarcinogenesis by HCV infection.2. Materials and methods
2.1. Plasmids
To construct the Core-expressing plasmid pcDNA3.1-Core, the
full-length HCV core sequence (genotype 1b) was cloned into
pcDNA3.1, as described in our previous report [17].
2.2. Cell culture
The human hepatoma cell line HepG2 were purchased from
ATCC (Manassas, VA), and stored in our laboratory. HepG2
stable cell lines were established by transfection with either
pcDNA3.1-Core or pcDNA3.1-GFP or an empty vector, followed
by selection with 500 lg/mL G418 (Gibco). Cells were grown in
DMEM medium supplemented with 10% fetal bovine serum (FBS)
(HyClone). Cells were incubated at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2. The culture medium was changed every
24 h.
2.3. RNA interference
The siRNAs were designed in accordance with Reynolds et al.
[18]. Transfection with a green ﬂuorescent protein (GFP)-speciﬁc
siRNA was used as negative control. The target sequences for siR-
NAs were as follows: GFP: 50-ACT ACC TGT TCC ATG GCC A-30, Core:50-AAG GCG ACA ACC TAT CCC CAA-30 [19], and NANOG: 50-CCA
GAC CTG GAA CAA TTC A-30 [20]. Non-targeting scrambled siRNA
was used to control for non-speciﬁc effects. The siRNAs were syn-
thesized by Gene Chem Co, Ltd. The synthetic siRNAs were trans-
fected into cells using Lipofectamine 2000 reagant (Invitrogen),
according to the manufacturer’s instructions. Total RNA was iso-
lated at 48 h post-transfection and protein lysates were prepared
72 h post-transfection.
2.4. Real-time PCR assays
Total RNA of HepG2 cells was extracted by RNAiso plus (Takara
Bio., Dalian, China) after cells reached about 90%. cDNA were syn-
thesized by using a reverse transcription kit (Takara Bio., Dalian,
China), and the real-time PCR assay was conducted with a SYBR
Premix Ex Tag (Takara Bio., Dalian, China). Forward primers,
50-CAG AAG GCC TCA GCA CCT AC-30 and 50-TGG CAC CCA GCA
CAA TGA A-30 and reverse primers, 50-ATT GTT CCA GGT CTG GTT
GC-30 and 50-CTA AGT CAT AGT CCG CCT AGA AGC A-30 were used
for NANOG and b-actin, respectively. The PCR reaction proceeded
as follows: 95 C for 30 s, then 35 cycles including 90 C for 30 s
and 60 C for 30 s. The results were analyzed by LC-480 system.
2.5. Western blotting assay
Western blot analysis was then performed for the indicated
proteins. Cells were washed with ice-cold PBS and then lysed.
An equal amount of protein from whole cell lysates was sepa-
rated by SDS–PAGE. Proteins were transferred onto PVDF mem-
branes, and were blocked with 5% non-fat milk in TBST for 1 h
at room temperature and then incubated with antibodies against
Core, NANOG (Abcam), stat3, phosphorylated-stat3, cyclin D1
(Cell Signal Technology), and c-tubulin (Sigma) at 4 C overnight.
After washing with TBST, membranes were incubated with
HRP-conjugated secondary antibody (Bio-Rad) for 1 h at room
temperature. The Supersignal West Pico Chemiluminescent
Substrate (Thermo USA) was used to visualize protein bands on
X-ray ﬁlms.
2.6. Cell proliferation assay
For the determination of cell growth rate, cells were seeded at
5  104 per well in 6-well plates and the total cell number in each
well was counted after incubating under the indicated conditions.
For MTT assay, cells were seeded at 1  103 per well in 96-well
plates and incubated under the indicated conditions. The
MTT-derived formazan developed by cells was quantiﬁed by mea-
suring absorbance at 550 nm.
2.7. Cell cycle analysis
Cell cycle proﬁle was analyzed using ﬂow cytometry. Brieﬂy,
1  106 cells were harvested and ﬁxed with ice-cold 75% ethanol
overnight, and incubated with propidium iodide (PI) (50 lg/mL)
(Sigma) in the dark at room temperature for 30 min. Flow cytomet-
ric analysis was performed on a Beckman Coulter EPICS analyzer. A
multicycle AV software was employed for calculating the cell cycle
phase distribution from the resultant DNA histogram.
2.8. Chromatin immunoprecipitation assay
The ChIP Kit (Millipore) was used according to the manufac-
turer’s instructions. Brieﬂy, Core-expressing HepG2 cells (107 per
assay) were bathed in 1% formaldehyde at 25 C for 10 min for
cross-linking of proteins and DNA and then lysed in SDS buffer
containing 1  protease inhibitor. DNA was sheared to 0.2- to
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noprecipitated with anti-phosphorylated-stat3 antibodies (Cell
Signal Technology), and a negative control rabbit IgG (Cell Signal
Technology). DNA released from precipitated complexes was
ampliﬁed by Q-PCR using NANOG primers (sense, 50-GCAGAG
TGC AGA GGA GAA TGA G-30; antisense, 50-GAG TGG GGT TCC
AGC ACT AA-30). The PCR reaction conditions were as follows:
denaturation at 50 C for 2 min, followed by 40 cycles of 95 C
(15 s), 60 C (15 s) and 72 C (32 s), and a ﬁnal extension at 72 C
for 2 min.
2.9. Statistical analysis
All statistical analysis were performed using SPSS 17.0software.
All data are representative of at least 3 separate experiments. Indi-
vidual data points were compared by 2-tailed Student’s t test;
P < 0.05 was considered statistically signiﬁcant.Fig. 1. HCV Core up-regulates NANOG expression. (A-a) Western blotting analyses show
(HepG2-Core), as compared to the HepG2 cells transfected with an empty vector (HepG2
Real-time PCR and Western blotting analyses showed that expression of NANOG mRNA
HepG2-vector and HepG2-GFP cells. b-Actin was used as a loading control for Real-time
analyses showed that expression of Core was signiﬁcantly down-regulated in HepG2-C
control. (b and c) Real-time PCR and Western blotting analyses showed that expression o
following the inhibition of Core by RNAi. b-Actin was used as a loading control for Real3. Results
3.1. HCV Core up-regulated NANOG expression
To explore the potential role of HCV Core in the up-regulation of
NANOG expression in HCC, we ﬁrst tested the effect of Core on
NANOG expression in a human hepatoma cell line HepG2. Stable
expression of Core induced up-regulation of NANOG protein level
(Fig. 1A-a and A-c). The level of NANOG mRNA in HepG2 cells, as
determined by real time PCR, was similarly increased by Core
(Fig. 1A-b).To further conﬁrm the relationship between Core and
NANOG, we measured NANOG expression following knockdown
of Core using a speciﬁc siRNA (Fig. 1B-a). The loss-of-function anal-
ysis revealed that NANOG expression at both the mRNA and pro-
tein level was reduced following the inhibition of Core (Fig. 1B-b
and B-c). Taken together, these results indicated that Core up-reg-
ulates NANOG expression at both the mRNA and protein level.ed that HCV Core was highly expressed in HepG2 cells stably transfected with Core
-vector) or with GFP (HepG2-GFP). c-Tubulin was used as loading control. (b and c)
and protein were signiﬁcantly up-regulated in HepG2-Core cells as compared to
PCR and c-tubulin as loading control for Western blotting. (B-a) Western blotting
ore cells following the inhibition of Core by RNAi. c-Tubulin was used as loading
f NANOG mRNA and protein were signiﬁcantly down-regulated in HepG2-Core cells
-time PCR and c-tubulin as loading control for Western blotting. ⁄P < 0.05.
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NANOG is an important self-renewal determinant in embryonic
stem cells [7]. In murine ESCs, Suzuki et al. found that phosphory-
lated stat3 can bind to the promoter region of NANOG and acti-
vated its transcription [21]. We therefore hypothesized that Core
transcriptionally up-regulates NANOG expression through stat3
phosphorylation in human hepatoma cells. To test this hypothesis,
we ﬁrst examined stat3 expression and its phosphorylated form
and downstream molecule cyclin D1 in Core-expressing HepG2
cells. We found levels of stat3 phosphorylation and cyclin D1
expression were increased in Core-expressing HepG2 cells as com-
pared to control cells, while the parental form of stat3 remained
unaffected (Fig. 2A). The loss-of-function analysis revealed that
both stat3 phosphorylation and cyclin D1 expression were down-
regulated following the inhibition of Core (Fig. 2B). In addition to
the Core-induced NANOG expression described above (Fig. 1A
and B), our results indicated that up-regulation of NANOG expres-
sion by Core may be associated with stat3 phosphorylation. To fur-
ther examine whether the regulation of NANOG expression by HCV
Core in human hepatic cancer cells is dependent on stat3 activa-
tion, we examined stat3 phosphorylation and NANOG expression
in response to a Jak inhibitor AG490 in Core-expressing HepG2Fig. 2. HCV Core up-regulated NANOG expression via stat3 pathway. (A) Western blottin
molecule cyclin D1 were up-regulated in HepG2-Core cells as compared to HepG2-vect
Tubulin was used as loading control. (B) Western blotting analyses showed that the expr
regulated in HepG2-Core cells following the inhibition of Core by RNAi, while the paren
Western blotting analyses showed that the expression of phosphorylated stat3, cyclin D
compared to HepG2-Core cells without AG490 treatment. c-Tubulin was used as loadincells. Jak is kinase of stat3 and Jak inhibitor AG490 was used to
antagonize the activation of stat3. We found that both stat3 phos-
phorylation and NANOG up-regulation in Core-expressing HepG2
cells were reversed by treatment of AG490 (Sigma, St Louis, MO,
USA) at the ﬁnal concentrations of 25 lM for 12 h (Fig. 2C), indicat-
ing that up-regulation of NANOG expression by Core was mediated
by stat3 phosphorylation and NANOG may be a downstream gene
of stat3 pathway. Taken together, these results suggested that Core
up-regulated NANOG expression via stat3 pathway.
3.3. Phosphorylated stat3 directly binds to the promoter of NANOG and
regulates its expression
Since the expression of NANOG were signiﬁcantly inhibited fol-
lowing the inhibition of stat3 phosphorylation, so we assume that
phosphorylated stat3 might regulate NANOG expression directly.
To test the hypothesis, we conducted chromatin immunoprecipita-
tion (ChIP) to determine whether the phosphorylated stat3 protein
can bind to the NANOG promoter region (Fig. 3). We searched the
ﬁrst 2000 bp of the promoter region of NANOG and found one po-
tential binding sites for the stat3 protein (Fig. 3A). After gather the
crosslink product of Core-expressing HepG2 cells, we used the
ultrasound to shear the chromatin DNA into an average size ofg analyses showed that the expression of phosphorylated stat3 and its downstream
or and HepG2-GFP cells, while the parental form of stat3 remained unaffected. c-
ession of phosphorylated stat3 and its downstream molecule cyclin D1 were down-
tal form of stat3 remained unaffected. c-Tubulin was used as loading control. (C)
1 and NANOG were down-regulated in HepG2-Core cells with AG490 treatment, as
g control.
Fig. 3. The phosphorylated stat3 protein can directly bind to the promoter of
NANOG. (A) The promoter region of NANOG contains a binding motifs (red) for the
stat3 protein at the nucleotide positions of 1124–1136. (B) Soluble chromatin
complexes were prepared from Core-expressing HepG2 cells as described in the
Section 2 and immunoprecipitated with 10 lg of a speciﬁc antibody against
phosphorylated stat3 at 4 C overnight. The immune complexes were pulled down
with protein A-agarose beads and cross-linking was reversed. The puriﬁed DNA was
analyzed by Q-PCR using the primers speciﬁc to the NANOG promoter region. M1:
DL 1 kb DNA marker; 1–6: sheared DNA, only these in line 3 are of 100–1000 bp to
be used for PCR ampliﬁcation. M2: DL2000 DNA marker. (C) A marked increase of
phosphorylated stat3 bound on the upstream of transcriptional start site of NANOG
was found upon HepG2-Core cells as compared with the HepG2-GFP and HepG2-
vector control in ChIP assay. Normal rabbit antibody added served as a negative
control. Error bars represent standard deviation (SD) from at least three indepen-
dent experiments.
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out according to the instruction of ChIP Chromatin immunoprecip-
itation Kit. Our Q-PCR ampliﬁcation experiments using the primer
pairs indicated that phosphorylated stat3 protein can directly bind
to the promoter region of NANOG (Fig. 3C). These results suggested
that activated stat3 regulates NANOG transcription in a direct way.
In addition to the results described above, our ﬁndings demon-
strate the positive link between HCV Core expression, STAT3 acti-
vation, and NANOG transcription.
3.4. Knockdown of NANOG inhibited expression of cyclin D1 and
blocked cell cycle of Core-expressing cells
In order to investigated the role of NANOG in regulating prolif-
eration of Core-expressing HepG2 cells, we ﬁrst examined whetherHCV Core stimulates cell growth as demonstrated by previous
reports [22,23]. According to direct cell counting data (Fig. 4A-a),
we found that the growth of Core-expressing cells (HepG2-Core)
was much faster as compared to HepG2 cells without Core expres-
sion (HepG2-vector and HepG2-GFP). FCM analysis revealed that
Core effectively stimulated cell cycle progression from G1 to S
phase (Fig. 4A-c and A-d). Both cell growth and FCM experiments
suggest that Core stimulates cell growth by enhancing cell cycle
progression from G1 to S phase. Western blotting analysis demon-
strated that NANOG and cell cycle related proteins cyclinD1
expression were signiﬁcantly increased in Core-expression cells
(Fig. 4A-b). Next, we examined whether down-regulation of NA-
NOG regulated cell proliferation of Core-expressing cells. Western
blotting analyses demonstrated that cyclinD1 expression were
signiﬁcantly reduced in NANOG-inhibited cells as compared to
Core-expressing cells (Fig. 4B-a). FCM analysis revealed that the
cell cycle was mainly blocked in the G0/G1 phases in the
NANOG-inhibited cells as compared to Core-expressing cells
(Fig. 4B-b). In the NANOG-inhibited cells, the G0/G1 ratio was
much higher than Core-expressing cells and the proportion of
S + G2/M was much lower than Core-expressing cells (Fig. 4B-c)
(⁄P < 0.05). These results suggested that NANOG may modulate
the growth and promote cell proliferation of the Core-expressing
cells via NANOG/cyclinD1 pathway.4. Discussion
Recently, Several recent studies have provided consistent evi-
dence for the role of NANOG as a potential human oncogene
[9,12,24]. Aberrant expression of NANOG during tumor develop-
ment was observed in a variety of different tumor types and cell
lines [25–28], including HCC [29]. In addition, transfection of
NANOG cDNA into 293 cells leads to malignant transformation
in vitro and tumor formation in vivo [30], and down-regulation
of NANOG results in decreased long-term clonal and clonogenic
growth, reduced proliferation and, in some cases, altered differen-
tiation [24]. Moreover, direct induction of HCC by Core in trans-
genic mice has been reported. These ﬁndings indicated that
NANOG plays particular important role in HCC carcinogenesis.
The association between hepatitis C virus (HCV) infection and
the risk of hepatocellular carcinoma (HCC) was established, but
the carcinogenic mechanism remains largely unknown. Among
oncoproteins of hepatitis virus, the Hepatitis B virus X protein
was found be associated with the up-regulation of NANOG expres-
sion in vitro and in vivo [31], and the NS5A, a non-structural protein
of HCV, have also been found to induce the expression of NANOG
together with alcohol [14]. The above discover implicated a poten-
tial role of hepatitis virus in regulating NANOG expression. There-
fore, science the core protein is a central oncogenic protein of
HCV, it is interesting to explore the molecular mechanism that
howNANOG is regulated by HCV Core in the process of HCV-related
HCC tumorigenesis and development. In the present study, we
showed that NANOG expression was up-regulated by HCV Core in
HepG2 cells. And the loss-of-function analysis conﬁrmed that
RNA interference-mediated knockdown of Core down-regulated
the expression of NANOG at both themRNA and protein level. These
results established a novel link between NANOG and Core in liver
cancer cells, indicating that stem cell marker NANOG may play a
role in HCV Core-associated hepatocellular carcinogenesis.
Bourguignon et al. reported that NANOG forms a complex with
the Stat3 in the nucleus leading to Stat3-speciﬁc transcriptional
activation and multidrug transporter, MDR1 (P-glycoprotein) gene
expression, which are associated with cell proliferation [32]. Stat3
has been found to be constitutively activated by phosphorylation
on tyrosine in HCC and also be prominently constitutively
Fig. 4. Knockdown of NANOG inhibited expression of cyclin D1 and blocked cell cycle of Core-expressing cells. (A-a) direct cell counting data showed that the growth of Core-
expressing cells (HepG2-Core) was much faster than HepG2 cells without Core expression (HepG2-vector and HepG2-GFP). (b) Western blotting analyses showed that the
expression of NANOG and cyclinD1 were signiﬁcantly up-regulated in HepG2-Core cells as compared to HepG2-vector and HepG2-GFP cells. c-tubulin was used as a loading
control. (c and d) Flow cytometry analyses showed that Core-expression induced an increase in the proportion of G2/M + S phase cells in HepG2-Core cells as compared to
HepG2-vector and HepG2-GFP cells. All experiments were repeated at least three times, ⁄P < 0.05. (B-a) Western blotting analyses showed that the expression of cyclinD1
were signiﬁcantly down-regulated following the inhibition of NANOG by RNAi in HepG2-Core cells. c-Tubulin was used as a loading control. (b and c) Flow cytometry
analyses showed that down-regulation of NANOG induced a decrease in the proportion of G2/M + S phase cells in HepG2-Core cells as compared to control cells. ⁄P < 0.05.
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ported that HCV Core activated stat3 through phosphorylation of
the critical tyrosine residue, leading to malignant transformation
and immortalization of human hepatocytes [5]. Thus, we hypothe-
size that Core-induced NANOG expression may be mediated by
activation of stat3 pathway. Indeed, we found that Core-induced
NANOG expression was associated with enforced phosphorylation
of stat3 protein, and was abolished by inhibition of stat3 phosphor-
ylation via AG490 treatment, indicating that HCV Core regulates
NANOG expression via stat3 pathway. There may be a possibility
that activated stat3 by HCV Core-induced phosphorylation in
Core-expressing cells may play its function on NANOG synthesis,
ultimately leading to expression of NANOG. Thus, we adopt the
ChIP assay to determine whether stat3 regulates NANOG expres-
sion in a direct way. Our ChIP assay conﬁrmed that phosphorylated
stat3 protein can directly bind to the promoter of NANOG. There-
fore, our ﬁndings demonstrated the positive connection between
Core expression, stat3 activation, and NANOG transcription. Fur-
thermore, the stat3-mediated NANOG up-regulation seems to
establish a novel molecular relationship between chronic inﬂam-
mation and stem cell marker NANOG for HCV Core, by which
chronic inﬂammatory states of HCV infection might generate a
microenvironment fostering tumor initiation in HCV-associated
cancers.
Previous studies have shown that expression of NANOG in
NIH3T3 promoted cells to enter into S phase and enhanced cell
proliferation [34], and down-regulation of NANOG in cancer cells
lead to inhibited cell proliferation [24].In consideration of HCV
Core protein can enhance the proliferation ability of human hepa-
toma cells [24],we hypothesize that NANOGmay play a role in pro-
motion of cell proliferation induced by HCV Core. In the present
study, we found that Core stimulated cell proliferation of human
hepatoma cells, and the Core-induced cell proliferation was
inhibited by down-regulation of NANOG, indicating that the
enhanced cell growth capacity and proliferative ability of Core-
expressing cells may be partially associated with up-regulation of
NANOG expression. We also demonstrated that the expression lev-
els of cyclinD1 is up-regulated in Core-expressing cells and down-
regulated following inhibition of NANOG. In addition, cyclinD1
promoter has been shown to contain the ATTA binding motifs for
NANOG protein [35], suggesting that NANOG may modulate cell
growth and promote cell proliferation through directly regulating
the cyclinD1 expression. Therefore, based on these observations,
we propose that Core plays a role during hepatocellular carcino-
genesis by stat3-mediated NANOG regulation and subsequently
enhanced cell proliferation. Our ﬁnding provides a new insight into
the mechanism of hepatocarcinogenesis by HCV infection.
In summary, we found that activity of stat3 was up-regulated
by HCV Core, and HCV core protein-induced NANOG expression
was largely attributed to the directly binding of phosphorylated
stat3 on the NANOG promoter region. In addition, knockdown of
NANOG blocked the cell cycle at the G0/G1 phases and inhibited
the cyclin D1 expression in Core-expressing cells. Altogether, these
results proposed a new mechanism by which HCV Core regulates
expression of NANOG. Our ﬁndings provide a new insight into
the mechanism of hepatocarcinogenesis by HCV infection, and
highlights STAT3 as an attractive molecular targets for prevent-
ing/treating HCV-related HCC. Interestingly, STAT3-speciﬁc target-
ing inhibitors are currently being tested in a number of cancer
therapy studies [36].
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